Numab Therapeutics is to support Kaken Pharmaceutical in identifying a multi-specific antibody candidate. The biotech start-up company has a unique technology platform that can help select potential candidates. Kaken Pharmaceutical will then develop the suitable candidates into a medication for inflammatory diseases.
As per the terms of the agreement, Kaken Pharmaceutical will fully fund Numab’s research work, explained a statement. In return, Kaken will obtain an option to conclude a license and co-development agreement after identification of the lead candidate.
Numab, which is headquartered in Pfäffikon, was founded in 2011. The start-up company already has a number of partnerships with pharmaceutical companies, whom it supports in developing immuno-oncology and immunology drugs in particular.
Kaken Pharmaceutical is based in Tokyo and concentrates on the development and commercialisation of new medications in the fields of immunology, inflammatory diseases, pain relief and fungal infections, as well as medical devices in the fields of orthopedics, dermatology and surgery.
